Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2.
Abstract
Phenotypic plasticity involves a process in which cells transiently acquire phenotypic
traits of another lineage. Two commonly studied types of phenotypic plasticity are
epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET).
In carcinomas, EMT drives invasion and metastatic dissemination, while MET is proposed
to play a role in metastatic colonization. Phenotypic plasticity in sarcomas is not
well studied; however, there is evidence that a subset of sarcomas undergo an MET-like
phenomenon. While the exact mechanisms by which these transitions occur remain largely
unknown, it is likely that some of the same master regulators that drive EMT and MET
in carcinomas also act in sarcomas. In this study, we combined mathematical models
with bench experiments to identify a core regulatory circuit that controls MET in
sarcomas. This circuit comprises the microRNA 200 (miR-200) family, ZEB1, and GRHL2.
Interestingly, combined expression of miR-200s and GRHL2 further upregulates epithelial
genes to induce MET. This effect is phenocopied by downregulation of either ZEB1 or
the ZEB1 cofactor, BRG1. In addition, an MET gene expression signature is prognostic
for improved overall survival in sarcoma patients. Together, our results suggest that
a miR-200, ZEB1, GRHL2 gene regulatory network may drive sarcoma cells to a more epithelial-like
state and that this likely has prognostic relevance.
Type
Journal articlePermalink
https://hdl.handle.net/10161/13882Published Version (Please cite this version)
10.1128/MCB.00373-16Publication Info
Somarelli, Jason A; Shetler, Samantha; Jolly, Mohit K; Wang, Xueyang; Bartholf Dewitt,
Suzanne; Hish, Alexander J; ... Garcia-Blanco, Mariano A (2016). Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression
of MicroRNA 200s and GRHL2. Mol Cell Biol, 36(19). pp. 2503-2513. 10.1128/MCB.00373-16. Retrieved from https://hdl.handle.net/10161/13882.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Andrew John Armstrong
Professor of Medicine
1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate
cancer 2. Novel designs of clinical trials and pharmacodynamic/translational studies
in prostate, kidney, bladder cancer 3. Pre-operative models for drug development of
novel agents in human testing in prostate cancer 4. Novel therapies and drug development
for prostate, renal, bladder, and testicular cancer 5. Design of rational combination
therapies in men with metastatic hormone-refra
Suzanne Bartholf DeWitt
Postdoctoral Associate
William Curtis Eward
Frank H. Bassett III, M. D. Associate Professor of Orthopaedic Surgery
I am an Orthopaedic Oncologist, with dual clinical degrees (MD and DVM). I treat
complex sarcomas in people and animals. My laboratory studies comparative oncology
- discoveries we can make about cancer by analyses across different species.
Mariano Agustin Garcia-Blanco
Adjunct Professor in the Molecular Genetics and Microbiology
Human and viral genes are complex genetic units of information that are tightly regulated.
The laboratory studies three aspects of this regulation: the interface between synthesis
of mammalian messenger RNAs and the processing events required to mature these transcripts,
the alternative processing of these messenger RNAs to produce multiple proteins from
one gene, and the regulation of gene expression in human pathogenic flaviviruses.
In the great majority of human transcripts
Jason Andrew Somarelli
Assistant Professor in Medicine
Alphabetical list of authors with Scholars@Duke profiles.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info